“Early Management after Self-Poisoning with an Organophosphorus or Carbamate Pesticide - a Treatment Protocol for Junior Doctors.” Critical Care / the Society of Critical Care Medicine 8 (6):R391–97.įrench, Robert N. “Pharmacological Treatment of Organophosphorus Insecticide Poisoning: The Old and the (possible) New.” British Journal of Clinical Pharmacology 81 (3):462–70.Įddleston, Michael, Andrew Dawson, Lakshman Karalliedde, Wasantha Dissanayake, Ariyasena Hittarage, Shifa Azher, and Nick A. “Management of Acute Organophosphorus Pesticide Poisoning.” The Lancet 371 (9612):597–607.Įddleston, Michael, and Fazle Rabbi Chowdhury. “Comparison of Current Recommended Regimens of Atropinization in Organophosphate Poisoning.” Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology 10 (2):143–47.Įddleston, Michael, Nick A. “Treatment of Drug-Induced Seizures.” British Journal of Clinical Pharmacology 81 (3):412–19.Ĭonnors, Nicholas J., Zachary H. “Use of Multi-Dose Activated Charcoal in Phenytoin Toxicity Secondary to Genetic Polymorphism.” Clinical Toxicology 53 (2):131–33.Ĭhen, Hsien-Yi, Timothy E. “Why Do the Results of Studies on the Effectiveness of Pralidoxime for Treatment of Organophosphate Poisoning Vary?”Ĭhan, Betty S. “Recent Advances in the Treatment of Organophosphorous Poisonings.” Iranian Journal of Medical Sciences 37 (2):74–91.īhalla, Ashish, and Surjit Singh.
#Atropine antidote for trial#
“Open-Label Randomized Clinical Trial of Atropine Bolus Injection versus Incremental Boluses plus Infusion for Organophosphate Poisoning in Bangladesh.” Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology 8 (2):108–17.īalali-Mood, Mahdi, and Hamidreza Saber. No stability data for atropine diluted in any of the compatible solutions.Ībedin, Mohammed Joynal, Abdullah Abu Sayeed, Ariful Basher, Richard J.The 0.4 mg/ml multidose vial by Sandoz contains a preservative (0.5% chlorobutanol).Ampoules and syringes of 0.4 and 0.6 mg/ml are intended for single use only and do not contain any preservatives.Y-site incompatibility : dantrolene, diazepam, pantoprazole, phenytoin, sulfamethoxazole - trimethoprim, thiopental.Y-site compatibility : aminophylline, amiodarone, atracurium, benztropine, bicarbonate (sodium), calcium (chlorine and gluconate), dexamethasone, digoxin, diphenhydramine, dobutamine, dopamine, ephedrine, esmolol, etomidate, famotidine, fentanyl, folic acid, furosemide, standard heparin, regular insulin, isoproterenol, ketamine, labetalol, lidocaine, magnesium (sulfate), mannitol, metoclopramide, metoprolol, midazolam, morphine, MVI, naloxone, nitroglycerin, sodium nitroprusside, norepinephrine, ondansetron, pentobarbital, phenobarbital, phentolamine, phenylephrine, phytonadione (vitamin K1), potassium (chloride), procainamide, prochlorperazine, propranolol, protamine, pyridoxine, ranitidine, succinylcholine, thiamine, vasopressin, verapamil.Compatible solutions : NS, D5W, D5W - NS, D5W - ½NS.Consult the pharmacist on duty at your health care facility. Possible alternative when IV or IO routes not accessible.Possible alternative to IV route, but slower onset of action.Examples using an ampoule with a concentration of 0.6 mg/ml:.10 mg (25 ml) in 75 ml of NS Final volume: 100 ml.5 mg (12.5 ml in 37.5 ml of NS Final volume: 50 ml.Examples using an ampoule with a concentration of 0.4 mg/ml.Transfer contents into an empty bag or syringe that can adapt to a syringe pump or volumetric pump.
Soins palliatifs, soins de fin de vie et décès.Centre d’expertise en sécurité de l’information (CESS).Centre d'excellence sur le vieillissement de Québec.Colloques, congrès, conférences et formations.Naloxone (extrahospital administration).Chelating agents (excluding Deferoxamine).Accès au dossier de l'usager - Archives.Soins palliatifs et soins de fin de vie.
Devenir fournisseur pour le CIUSSS de la Capitale-Nationale.Bureau du partenariat avec l’usager et de l’éthique (BPUE).Portrait of the CIUSSS de la Capitale-Nationale.
0 kommentar(er)
